In the article ‘CRISPR-Cas9-Mediated Silencing of CD44 in Human Highly Metastatic Osteosarcoma Cells’ [Cellular Physiology and Biochemistry (2018) 46 (3): 1218–1230. https://doi. org/10.1159/000489072] by Liu et al.
After reviewing the publication “CRISPR-Cas9-Mediated Silencing of CD44 in Human Highly Metastatic Osteosarcoma Cells”, the author identified errors in Figure 4A, the immunofluorescence image, and Figure 4B, the CD44 Western Blot bands of the 143B cell line. These inaccuracies occurred due to the erroneous uploading of the original images. All authors consent on this necessary correction and all the results and conclusions of the article remain unchanged. The authors would like to apologise for any inconvenience caused. This Erratum is published following an independent investigation overseen by the Deputy Minister for Scientific Research at the 2nd Xiangya Hospital of Central South University oversaw which found that the original data was reflective of the conditions described in the article.
Fig. 4: (A) Fluorescence analysis showed that GFP was detected in MNNG/HOS-pEGFP-N3, MNNG/HOS- CD44-Cas9-GFP, 143-B-CD44-Cas9-GFP, and 143-B-pEGFP-N3 cells, which suggests that MNNG/HOS and 143-B cells were successfully transfected with CD44-Cas9-GFP or pEGFP-N3. (B) Western blotting analysis confirmed that CD44 protein expression was significantly inhibited in MMNG/HOS and 143B cells transfected with C-Cas9-GFP. Furthermore, Cas9 protein was expressed in MNNG/HOS and 143B cells transfected with CD44-Cas9-GFP. CD44 expression was repressed 10.13±2.46 fold (*p< 0.01) and 9.56±1.79 fold (**p< 0.01) in MNNG/HOS and 143B cells transfected with CD44-Cas9-GFP, respectively.